The Food and Drug Administration will review MAP Pharmaceuticals Inc.’s experimental migraine drug Levadex, the Mountain View, Calif., company said. Levadex is an orally inhaled drug proposed to treat migraines in adults. The biopharmaceutical company focuses on developing new therapies to address patient needs in neurology.
MAP Pharmaceuticals Inc.
You've reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week